病菌感染治療市場 - 全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、藥物類別、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球病菌感染治療市場預計將從 2025 年的 23.1 億美元成長到 2031 年的 33.4 億美元，複合年成長率為 6.34%。

該市場涵蓋專門的抗生素療法，包括先進的BETA-內醯胺類抗生素、Aminoglycosides抗生素和聯合治療，主要針對機會性感染且通常具有多重抗藥性的革蘭氏陰性菌。市場成長的主要驅動力是院內感染發生率的上升，尤其是人工呼吸器相關性肺炎和導尿管相關尿道感染，這些感染推動了對有效治療方法的需求。此外，免疫力缺乏人群數量的增加，包括囊腫纖維化患者和接受化療的患者，也是市場持續擴張的主要促進因素。

儘管有這些正面因素，但由於研發生態系統脆弱，新抗生素研發成本高而商業性回報低，市場仍面臨嚴峻挑戰。這種經濟失衡導致該領域科學人才數量令人擔憂地下降。根據抗菌素抗藥性產業聯盟的數據，到2024年，全球從事抗菌素抗藥性研究的人員將僅約3000人，這凸顯了嚴重的人才短缺，阻礙了針對銅綠假單胞菌等重點病原體的創新治療方法的開發。

市場促進因素

囊腫纖維化(CF) 和慢性呼吸道疾病的高發生率是全球病菌感染治療市場的主要動力。銅綠假單胞菌是一種機會性致病菌，它能在囊性纖維化患者氣道中常見的濃稠粘液中大量繁殖，導致慢性且嚴重的感染疾病，需要持續使用抗生素治療。這種對持續控制菌叢的需求推動了吸入式抗生素和抑制療法的持續需求，為製藥公司提供了穩定的收入來源。根據囊腫纖維化基金會於 2025 年 9 月發布的《2024 年患者登記年度數據報告》，約 23% 的囊腫纖維化患者被診斷出患有病菌感染感染，這凸顯了針對這一脆弱患者群體的高效治療方法的迫切臨床需求。

市場成長也得益於一系列新型抗菌藥物的強勁臨床研發管線，這些藥物旨在彌補現有抗生素的不足。在抗藥性威脅日益加劇的背景下，噬菌體療法和合成抗感染藥物等創新治療方法的研發正在加速推進，並正處於關鍵的臨床試驗階段。例如，2025年7月，BiomX公司公佈了其1b/2a期臨床試驗的數據，結果顯示，其霧化噬菌體混合物BX004在患有慢性感染疾病的囊腫纖維化（CF）患者中，與安慰劑相比，細菌載量降低了2.7 log10。此外，該領域也受惠於針對相關技術的專款支持。 2025年2月，CARB-X向Pearl Diagnostics公司撥款100萬美元，用於開發一種用於檢測銅綠假單胞菌肺炎的新型快速診斷測試，從而促進了市場發展生態系統的繁榮。

市場挑戰

限制全球病菌感染治療市場的主要障礙是研發領域的經濟不穩定性。將新型抗生素推向市場所需的巨額投資與最終較低的商業性價值之間存在巨大差距，這嚴重阻礙了製藥公司的積極性。這種低投資報酬率迫使許多大型公司退出抗菌藥物領域，導致研發管線捉襟見肘。因此，市場目前依賴中小型生物技術公司，而這些公司往往缺乏足夠的資金將候選藥物推進到後期臨床試驗階段。由此，治療多重抗藥性細菌感染所需的新治療方法的推出被推遲。

這種停滯不前在近期行業統計數據中得到了清晰體現，這些數據凸顯了嚴重的研發管線危機。國際藥品製造商協會聯合會（IFPMA）在2024年報告稱，僅有一種抗生素候選藥物處於針對四種被視為首要目標的細菌病原體的III期臨床試驗階段，尤其是銅綠假單胞菌。後期治療方案的匱乏凸顯了市場失靈的實際後果，因為研發相關的財務風險阻礙了為患者提供有效新治療方法所需的投資。

市場趨勢

鐵載體抗生素的興起正在改變治療模式。這類抗生素利用細菌本身的鐵吸收系統，繞過複雜的抗藥性屏障。與依賴被動擴散的傳統抗生素不同，這些「特洛伊木馬」化合物能夠主動穿透多重抗藥性菌株的外膜，填補了金屬BETA-內醯胺酶和排放泵介導的抗藥性病原體治療中的關鍵空白。這種創新方法在對標準治療無效的難治性病例中取得了顯著的臨床成功。例如，在2025年4月舉行的「ESCMID Global 2025」記者會上，鹽野義製藥株式會社宣布，PROVE試驗顯示，使用鐵載體頭孢菌素類抗生素頭孢地洛治療確診的病菌感染患者的臨床治癒率達到73.1%。

同時，市場對旨在破壞氣道和燒傷創面中慢性定植保護層的抗病原體和生物膜破壞療法的關注度日益提高。這一趨勢正將研究重點從簡單的殺菌作用轉向破壞保護銅綠假單胞菌免受傳統抗生素治療和免疫反應侵害的生物膜結構。研究人員正持續開發抑制細胞能量代謝和生物膜完整性的合成抗感染藥物，以在不誘導抗藥性的情況下降低細菌量。特別是，Recce Pharmaceuticals在其2025年11月發布的「2026會計年度第一季財務業績和業務亮點」報告中指出，其領先的合成候選化合物R327G在治療開始後的第8天，使銅綠假單胞菌感染的燒傷創面中的細菌載量降低了約4個對數級。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：病菌感染治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（單藥治療、聯合治療）
  • 藥物類型（Aminoglycosides、頭孢菌素類、碳青黴烯類、單環胺基類、其他）
  • 給藥途徑（鼻內、口服、靜脈注射）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美銅綠病菌感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲病菌感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區病菌感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲病菌感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲病菌感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球病菌感染治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Allergan, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• AstraZeneca PLC.
• Merck & Co. Inc.
• Bristol-Myers Squibb Co.
• Janssen Pharmaceuticals Inc.
• Lupin Pharmaceuticals, Inc.
• Baxter International Inc.
• Sanofi SA.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pseudomonas Aeruginosa Infection Treatment Market is projected to expand from USD 2.31 Billion in 2025 to USD 3.34 Billion by 2031, reflecting a compound annual growth rate of 6.34%. This market comprises a specialized array of antimicrobial pharmacotherapies, such as advanced beta-lactams, aminoglycosides, and combination therapies, designed to target this opportunistic and frequently multidrug-resistant Gram-negative bacterium. Growth is largely underpinned by the increasing incidence of hospital-acquired infections, specifically ventilator-associated pneumonia and catheter-associated urinary tract infections, which sustain demand for effective treatments. Additionally, the growing population of immunocompromised individuals, including those battling cystic fibrosis or undergoing chemotherapy, acts as a primary catalyst for continued market expansion.

Despite these positive drivers, the market faces significant hurdles due to a fragile research and development ecosystem marked by exorbitant development costs and low commercial returns for novel antibiotics. This economic imbalance has resulted in a worrying reduction in scientific expertise within the field. Data from the AMR Industry Alliance indicates that in 2024, the global workforce focused on antimicrobial resistance research comprised roughly 3,000 professionals, underscoring a critical shortage of talent that hampers the creation of innovative therapies for priority pathogens like Pseudomonas aeruginosa.

Market Driver

The significant prevalence of cystic fibrosis (CF) and chronic respiratory conditions acts as a primary engine for the Global Pseudomonas Aeruginosa Infection Treatment Market. As an opportunistic pathogen, Pseudomonas aeruginosa prospers in the dense, viscous mucus typical of CF airways, causing chronic and debilitating infections that demand ongoing antimicrobial control. This necessity for persistent colonization management drives a continuous need for inhaled antibiotics and suppressive regimens, ensuring a steady revenue flow for pharmaceutical companies. According to the '2024 Patient Registry Annual Data Report' released by the Cystic Fibrosis Foundation in September 2025, about 23% of cystic fibrosis patients were diagnosed with a Pseudomonas aeruginosa infection, highlighting the urgent clinical requirement for effective therapies in this vulnerable group.

Market growth is further stimulated by a strong clinical pipeline of novel antimicrobial agents aimed at addressing the shortcomings of current antibiotics. The rising danger of drug resistance has spurred the advancement of innovative treatment modalities, such as bacteriophage therapies and synthetic anti-infectives, which are progressing through essential clinical trials. For example, BiomX reported in July 2025 that data from its 'Phase 1b/2a trial' showed its nebulized phage cocktail, BX004, resulted in a 2.7 log10 reduction in bacterial load in CF patients with chronic infections compared to a placebo. Additionally, the sector benefits from targeted funding for supportive technologies; in February 2025, CARB-X granted $1 million to Pearl Diagnostics to develop a new rapid assay for Pseudomonas aeruginosa pneumonia, thereby boosting the market's developmental ecosystem.

Market Challenge

A major obstacle restricting the Global Pseudomonas Aeruginosa Infection Treatment Market is the economic instability characterizing the research and development sector. The disparity between the immense investment needed to launch a new antibiotic and the subsequent low commercial value generates a significant disincentive for pharmaceutical developers. This poor return on investment has compelled numerous large companies to abandon the antimicrobial field, leaving the pipeline precariously thin and reliant on smaller biotechnology firms that often lack the funds to navigate candidates through late-stage trials. As a result, the deployment of novel therapies essential for treating multidrug-resistant strains is being delayed.

This stagnation is clearly reflected in recent industry statistics that highlight a severe pipeline crisis. The International Federation of Pharmaceutical Manufacturers and Associations reported in 2024 that there was only a single antibiotic candidate in Phase III clinical trials addressing the collective four bacterial pathogens deemed critical priorities, which specifically includes Pseudomonas aeruginosa. This scarcity of late-stage options emphasizes the tangible consequences of market failure, as the financial hazards linked to development discourage the investment required to deliver effective new treatments to patients.

Market Trends

The therapeutic landscape is being transformed by the rise of Siderophore-Based Antimicrobial Agents, which utilize the bacterium's own iron-uptake systems to circumvent complex resistance barriers. Distinct from traditional antibiotics that depend on passive diffusion, these "Trojan horse" compounds actively permeate the outer membrane of multidrug-resistant strains, filling a vital gap in treating pathogens possessing metallo-beta-lactamases and efflux pump-mediated resistance. This innovative approach has yielded significant clinical success in hard-to-treat scenarios where standard treatments are ineffective. For example, Shionogi & Co., Ltd. announced in an April 2025 press release regarding the 'ESCMID Global 2025' that the PROVE study showed a clinical cure rate of 73.1% in patients with confirmed Pseudomonas aeruginosa infections treated with the siderophore-cephalosporin cefiderocol.

Simultaneously, the market is observing a growing emphasis on Anti-Virulence and Biofilm-Disrupting Therapies aimed at dismantling the protective layers that enable chronic colonization in respiratory tracts and burn wounds. This trend shifts focus from simple bactericidal activity to destabilizing biofilm structures that protect Pseudomonas aeruginosa from conventional antibiotic treatments and immune responses. Researchers are increasingly developing synthetic anti-infectives that interrupt cellular energy and biofilm integrity to lower bacterial loads without provoking further resistance. Notably, Recce Pharmaceuticals reported in its 'Q1 FY2026 Results and Operational Highlights' in November 2025 that its primary synthetic candidate, R327G, accomplished an approximate 4-log reduction in bacterial burden in Pseudomonas aeruginosa-infected burn wounds by the eighth day of treatment.

Key Market Players

• Allergan, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• AstraZeneca PLC.
• Merck & Co. Inc.
• Bristol-Myers Squibb Co.
• Janssen Pharmaceuticals Inc.
• Lupin Pharmaceuticals, Inc.
• Baxter International Inc.
• Sanofi SA.

Report Scope

In this report, the Global Pseudomonas Aeruginosa Infection Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pseudomonas Aeruginosa Infection Treatment Market, By Medication Type

• Monotherapy
• Combination Therapy

Pseudomonas Aeruginosa Infection Treatment Market, By Drug Type

• Aminoglycoside
• Cephalosporin
• Carbapenem
• Monobactam
• Others

Pseudomonas Aeruginosa Infection Treatment Market, By Route Of Administration

• Nasal
• Oral
• Intravenous

Pseudomonas Aeruginosa Infection Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Pseudomonas Aeruginosa Infection Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pseudomonas Aeruginosa Infection Treatment Market.

Available Customizations:

Global Pseudomonas Aeruginosa Infection Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Medication Type (Monotherapy, Combination Therapy)
  • 5.2.2. By Drug Type (Aminoglycoside, Cephalosporin, Carbapenem, Monobactam, Others)
  • 5.2.3. By Route Of Administration (Nasal, Oral, Intravenous)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Medication Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route Of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Medication Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route Of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Medication Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route Of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Medication Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route Of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Medication Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route Of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Medication Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route Of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Medication Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route Of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Medication Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route Of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Medication Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route Of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Medication Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route Of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Medication Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route Of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Medication Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route Of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Medication Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route Of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Medication Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route Of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Medication Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route Of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Medication Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route Of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Medication Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route Of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Medication Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route Of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Medication Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route Of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Medication Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route Of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Pseudomonas Aeruginosa Infection Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Medication Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route Of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Medication Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route Of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Medication Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route Of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Pseudomonas Aeruginosa Infection Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Medication Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route Of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pseudomonas Aeruginosa Infection Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Allergan, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Pfizer Inc.
• 15.4. AstraZeneca PLC.
• 15.5. Merck & Co. Inc.
• 15.6. Bristol-Myers Squibb Co.
• 15.7. Janssen Pharmaceuticals Inc.
• 15.8. Lupin Pharmaceuticals, Inc.
• 15.9. Baxter International Inc.
• 15.10. Sanofi SA.

16. Strategic Recommendations

17. About Us & Disclaimer